Amneal Pharmaceuticals (AMRX) announced that the FDA has approved Brekiya injection, the first and only dihydroergotamine autoinjector for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. The product will be available for appropriate patients in the second half of 2025.
Brekiya autoinjector provides patients with the potential for sustained pain relief in a self-administered form. It contains the same medication used in hospitals, now in a ready-to-use device. Brekiya autoinjector does not require refrigeration, assembly, or priming of the device.
Shares of Amneal Pharmaceuticals are up 6% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.